SCHEMBL3277355

SCHEMBL3277355

CCc1cc(-c2nnc(-c3cc(C)nc(N(CC)CC)c3)o2)cc(C)c1OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 8/20 0.59
S1PR3 Q99500 6/20 0.47
TSHR P16473 4/20 0.39
MYC P01106 1/20 0.37
ALDH1A1 P00352 5/20 0.36
KDM4E B2RXH2 4/20 0.36
USP2 O75604 2/20 0.36
LMNA P02545 2/20 0.36
HSD17B10 Q99714 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
MAPT P10636 3/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
HTT P42858 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HPGD P15428 2/20 0.35
BRD4 O60885 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
HTR1D P28221 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3276567 0.86 S1PR1 (0.45) S1PR1S1PR3TSHRALDH1A1SMN1; SMN2
SCHEMBL27752453 0.83 S1PR1 (0.44) S1PR1S1PR3TSHRMYCALDH1A1
SCHEMBL3221506 0.79 TSHR (0.45) S1PR1S1PR3TSHRMYCALDH1A1
SCHEMBL1175809 0.78 S1PR1 (0.48) S1PR1S1PR3TSHRMYCALDH1A1
SCHEMBL2545632 0.78 S1PR1 (0.47) S1PR1S1PR3TSHRMYCALDH1A1
SCHEMBL3276104 0.77 S1PR1 (0.56) S1PR1S1PR3ALDH1A1KDM4EUSP2
SCHEMBL3282976 0.76 S1PR1 (0.40) S1PR1S1PR3TSHRKDM4ELMNA
SCHEMBL1188343 0.76 ALDH1A1 (0.40) S1PR1S1PR3TSHRMYCALDH1A1
SCHEMBL3276284 0.75 S1PR1 (1.00) S1PR1S1PR3
SCHEMBL3276292 0.75 S1PR1 (1.00) S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125797-B1 AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2014-01-15 EP disclosed
US-8592460-B2 Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2013-11-26 US disclosed
US-20100087417-A1 AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2010-04-08 US disclosed
EP-2125797-A1 AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2009-12-02 EP disclosed
WO-2008114157-A1 AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087417-A1 AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS S1PR1, S1PR3, S1PR4 S1PR1 1/4885S1PR3 2/4885TSHR 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.